Randomized Phase II Study of Gemcitabine (GEM) Versus GEM+TS-1 for Advanced Pancreatic Cancer
20 Years
75 Years
Both
Pancreatic Cancer
Trial Information
Randomized Phase II Study of Gemcitabine (GEM) Versus GEM+TS-1 for Advanced Pancreatic Cancer
Pancreatic cancer is the fifth leading cause of cancer death in the United States. It is
difficult to diagnose at its early stage and only 10-20% of patients are candidates for
resection with 5-year survival rate of less than 10%. Patients with unresectable pancreatic
cancer has a poor prognosis. Gemcitabine, a cytidine analogue, is the standard
chemotherapeutic agent for the disease with median survival time(MST) ranging from 6 to 8
months. Phase Ⅲ study showed that combinations with other drugs, such as oxaliplatine or
CDDP, did not contribute to survival time. TS-1, a new oral fluoropyrimidine which consists
of the 5-FU prodrug tegafur (ftorafur, FT) and two enzyme inhibitors, CDHP
(5-chloro-2,4-dihydroxypyridine) and OXO (potassium oxonate), in a molar ratio of 1(FT):0.4
(CDHP):1(OXO), is commercially available since late 90'in Japan. Phase II trials have
demonstrated that S-1 was effective as a single agent for treatment of gastric (RR 44.6%),
colorectal (RR 37.4%), head and neck, breast, non-small cell lung, and pancreatic
cancers(20%). A combination of gemcitabine and TS-1 is found to be effective and promising
in phase Ⅱ trial for metastatic pancreatic carcinoma in selected subjects, but the
combination therapy has high rate of side effects. This phase Ⅱ randomized controlled study
compares efficacy and feasibility of GEM+S-1 with GEM alone in patients with locally
advanced and metastatic pancreatic cancer and performance status of 0-2, aiming at patients
in rather ordinary clinical settings.
Inclusion Criteria:
1. Histologically or cytologically proven unresectable pancreatic carcinoma
2. There must be measurable lesions with multislice CT
3. ECOG Performance status 0-2
4. No other active cancer
5. No previous therapy such as radiotherapy, chemotherapy and immunotherapy
6. Adequate organ functions are preserved as WBC more than 4000/mm3,Hb more than
8.0g/dl,neutrophil more than 2000/mm3,platlet more than 100,000/mm3, AST less than
2.5 x normal or less than 5.0 x normal if the patient had known liver metastasis,
bilirubin less than 2.0mg/dl, Ccr more than 60ml/min
7. No serious complications
8. Be able to eat food
9. Life expectancy of more than 8 weeks duration
10. Informed consent is obtained-
Exclusion Criteria:
1. Interstitial pneumonia
2. Uncontrollable diabetes, liver dysfunction, angina pectoris,or myocardial infarction
with its onset within 3 months
3. Serious infection
4. Pregnant or lactating females
5. History of serious drug allergy
6. Serious other complications
7. Uncontrolled mental disorders -
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
response rate
Outcome Time Frame:
during observation
Safety Issue:
No
Principal Investigator
Takaaki Ikari, MD. PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Cancer Institute Ariake Hospital
Authority:
Japan: Ministry of Health, Labor and Welfare
Study ID:
JACCRO PC-01
NCT ID:
NCT00514163
Start Date:
June 2007
Completion Date:
December 2010
Related Keywords:
- Pancreatic Cancer
- pancreatic carcinoma
- gemcitabine
- S-1
- phaseⅡstudy
- Pancreatic Neoplasms
Name | Location |
|---|
